Predicted to enable alditol:NADP+ 1-oxidoreductase activity. Predicted to be located in cytoplasm. Predicted to be active in cytosol. Orthologous to human AKR1E2 (aldo-keto reductase family 1 member E2); INTERACTS WITH (+)-schisandrin B; 2,2',4,4'-Tetrabromodiphenyl ether; 2,3,7,8-tetrachlorodibenzodioxine.
1,5-anhydro-D-fructose reductase; AF reductase; Akr1cl2; Akr1e1; aldo-keto reductase family 1 member C-like protein 2; aldo-keto reductase family 1 member E2; aldo-keto reductase family 1, member C-like 2; aldo-keto reductase family 1, member E1; LOC307091; MGC105536
[Clofibrate co-treated with Acetaminophen] affects the expression of AKR1E1 mRNA and PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of AKR1E1 mRNA]
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1E2 mRNA
[Clofibrate co-treated with Acetaminophen] affects the expression of AKR1E1 mRNA and PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of AKR1E1 mRNA]
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1E2 mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1E2 mRNA